Flt3 ligand does not differentiate between parkinsonian disorders

Movement Disorders

Volumn 29, Issue 10, 2014, Pages 1319-1322

  Silajdžić, Edina ^a   Constantinescu, Radu ^b   Holmberg, Björn ^b   Björkqvist, Maria ^a   Hansson, Oskar ^c,d  

^a LUND UNIVERSITY   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Biomarker; Flt3 ligand; Multiple system atrophy; Parkinson's disease; Progressive supranuclear palsy

Indexed keywords

BIOLOGICAL MARKER; FLT3 LIGAND; FLT3 LIGAND PROTEIN; MEMBRANE PROTEIN;

ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; COHORT ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PARKINSON DISEASE; PARKINSONISM; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN BLOOD LEVEL; SHY DRAGER SYNDROME; ANALYSIS OF VARIANCE; CEREBROSPINAL FLUID; SEVERITY OF ILLNESS INDEX;

AGED; ANALYSIS OF VARIANCE; HUMANS; MEMBRANE PROTEINS; MIDDLE AGED; MULTIPLE SYSTEM ATROPHY; PARKINSONIAN DISORDERS; SEVERITY OF ILLNESS INDEX; SUPRANUCLEAR PALSY, PROGRESSIVE;

EID: 84908383699     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25948     Document Type: Article

References (14)

1. Colosimo C. Nonmotor presesntations of multiple system atrophy. Nat Rev Neurol 2011;7:295-298.
2. Jellinger KA. Neuropathological spectrum of synucleinopathies. Mov Disord 2003;18(Suppl 6):S2-S12.
3. Meara J, Bhowmick BK, Hobson P. Accuracy of diagnosis in patients with presumed Parkinson's disease. Age Ageing 1999;28: 99-102.
4. Schrag A, Ben-Shlomo Y, Quinn N. How valid is the clinical diagnosis of Parkinson's disease in the community? J Neurol Neurosurg Psychiatry 2002;73:529-534.
5. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
6. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 1992;42:1142-1146.
7. Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 2001;57:1497-1499.
8. Shi M, Bradner J, Hancock AM, et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol 2011;69:570-580.
9. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56:33-39.
10. Gilman S, Low PA, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci 1999;163:94-98.
11. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996;47:1-9.
12. Hall S, Ohrfelt A, Constantinescu R, et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol 2012;69:1445-1452.
13. Drexler HG, Quentmeier H. FLT3: receptor and ligand. Growth Factors 2004;22:71-73.
14. Ilzecka J. Cerebrospinal fluid Flt3 ligand level in patients with amyotrophic lateral sclerosis. Acta Neurol Scand 2006;114:205-209.